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Induction and prevention of radiocontrast-induced nephropathy in
dogs with heart failure. Radiocontrast-induced nephropathy (RCIN) is a
clinically important cause of acute renal failure with no effective
treatment. Recognizing the high incidence of RCIN in humans with
severe congestive heart failure (CHF), this study was designed to test
the hypotheses that dogs with experimental CHF are at increased risk
for RCIN and that pharmacologic renal levels of atnal natriuretic factor
(ANF) can prevent RCIN in this model. In chronic experiments, three
groups of five conscious dogs received intravenous radiocontrast (7
mi/kg). One group consisted of normal controls, while the two other
groups had experimental CHF induced by eight days of ventricular
pacing at 250 beats per minute. One of the CHF groups received an
infusion of ANF (30 ng/kg/min) into the suprarenal aorta for one hour
before, during and alter the infusion of radiocontrast to achieve
pharmacologic renal plasma levels. Renal function remained stable in
the normal controls in contrast to the consistent decreases in daily
creatinine clearance during the five days following radiocontrast in
experimental CHF. In addition, ANF prevented radiocontrast-induced
reductions in creatinine clearance in dogs with experimental CHF.
Additional studies performed in two groups of anesthetized dogs with
experimental CHF demonstrated that, in this model of RCIN, the
reduction in renal function appears biphasic, and the action of ANF
may be to increase glomerular filtration rate prior to radiocontrast, thus
allowing a maintenance of renal function during and after radiocontrast.
Radiocontrast-induced nephropathy (RCIN) has emerged as
an increasingly important clinical form of acute renal failure. As
emphasized by recent reviews [1, 2], recently described animal
models have helped elucidate the pathophysiology of RCIN.
The studies by Van et al [3] suggest that reversible decreases in
the glomerular ultrafiltration coefficient account for renal dys-
function following radiocontrast. Alternatively, the studies by
Heyman et al [4] implicate medullary hypoxia, particularly
affecting the medullary thick ascending limb, in the pathogen-
esis of RCIN. In addition, the conditions required to induce
acute renal failure in these models, namely chronic sodium
depletion and prostaglandin inhibition, may provide insight into
the mechanisms through which certain conditions predispose to
RCIN.
Atrial natnuretic factor (ANF) is an endogenous peptide
hormone of cardiac ongin with potent natriuretic, diuretic and
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vasorelaxant properties. When administered at pharmacologic
doses, ANF has preferential renal hemodynamic actions, in-
cluding the ability to increase glomerular filtration rate (GFR)
via afferent arteriolar dilation and efferent arteriolar constric-
tion [5] and perhaps via increases in the glomerular ultrafiltra-
tion coefficient [6]. Recently, several studies have reported
prophylactic and therapeutic effects of synthetic ANF in sev-
eral animal models of acute ischemic renal failure [7—li]. To
date, the potential role of ANF in prophylaxis of RCIN is
undefined.
The present studies were designed to extend the findings of
the two important animal models described above [3, 4] by
investigating the renal effects of radiocontrast in congestive
heart failure (CHF), a pathophysiologic condition which predis-
poses to RCIN in humans [12]. The resulting clinically relevant
animal was used to test the hypothesis that pharmacologic renal
concentrations of ANF can prevent acute and chronic reduc-
tions in GFR following intravenous radiocontrast.
Methods
All studies were performed on mongrel dogs of either sex
weighing between 16 and 25 kg, fed normal dog chow (Lab
Canine Diet #5006, Purina Mills, Inc., St. Louis, Missouri,
USA), and allowed free access to tap water. Dogs were studied
in either a chronic conscious setting or in an acute anesthetized
state. All animal studies conformed to the guiding principles of
the American Physiological Society.
Chronic studies in anesthetized dogs
These experiments were performed on three groups of five
dogs housed in individual metabolic cages for a period of three
weeks. One of these groups consisted of normal controls
(Group 1). In the other two groups, experimental CHF was
produced by eight days of rapid ventricular pacing. This exper-
imental model has been found to produce consistently a state of
low output cardiac failure with a constellation of cardiovascu-
lar, renal and neurohumoral abnormalities characteristic of
chronic primary myocardial failure [13, 14].
In Groups 2 and 3, programmable pacemakers (Model 8426,
Medtronic, Minneapolis, Minnesota, USA) were implanted 11
to 13 days prior to acute experiments. Under pentobarbital
anesthesia (30 mg/kg) and via a left thoracotomy and pen-
cardiectomy, the heart was exposed and a screw-in epicardial
pacemaker lead was implanted into the right ventricle. The
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pacemaker lead was connected to a pacemaker implanted
subcutaneously in the chest. In addition, at the time of pace-
maker implantation, a polyethylene catheter (PE 240, Clay
Adams, Parsippany, New Jersey, USA) was placed via a
femoral artery into the aorta at least 6 cm above the renal
arteries. The catheter was tunnelled subcutaneously from the
femoral artery to the back of the neck where it was exteriorized
and capped. The dogs were allowed to recover over a three day
period, during which they received prophylactic antibiotic
treatment with clindamycin and Combiotic' (Pfizer, Inc., New
York, NY, USA). The aortic catheter was flushed daily with a
solution of heparin and penicillin to maintain patency and
bacteriostasis. Following recovery from surgery, the pace-
maker was programmed to 250 beats per minute and pacing
continued at this rate for the remainder of these experiments.
After six days of rapid ventricular pacing, or non-pacing in
the normal controls, a baseline 48-hour urinary collection was
performed. A venous blood sample was drawn percutaneously
at the conclusion of this and subsequent clearance periods. At
the conclusion of the baseline urinary collection, the dogs were
placed in a minimally restraining sling and an intravenous
catheter was inserted percutaneously into a foreleg vein. A
suprarenal infusion of either saline vehicle (Group 2) or ANF,
30 nglkg/min in I mI/mm saline, (Group 3) was initiated in the
dogs with experimental CHF. The atrial peptide used in these
and the acute experiments was 28aa, a-human-ANF (Peninsula
Laboratories, Inc., Belmont, California, USA). After a 20-
minute lead-in period for the ANF or vehicle, the radiocontrast
agent (VascorayR, Mallinkrodt, Inc., St. Louis, Missouri, USA)
was infused intravenously at a dose of 7 mI/kg over a 10 minute
period. The suprarenal ANF/vehicle infusion was continued for
30 minutes following the radiocontrast infusion. The dogs were
returned to metabolic cages for a series of six consecutive
24-hour urine collections. Dogs were allowed free access to tap
water beginning 30 minutes after radiocontrast upon returning
to metabolic cages.
Acute studies in anesthetized dogs
Acute experiments were performed on two groups of six dogs
with experimental CHF produced by eight days of rapid ven-
tricular pacing. Programmable pacemakers were implanted II
to 13 days prior to acute experiments as described for the
chronic experiments. Three to five days after pacemaker im-
plantation, the pacemaker was programmed to 250 beats per
minute. The dogs were paced for eight days and fasted over-
night prior to acute experiments.
On the day of the acute experiment, the dogs were anesthe-
tized with fentanyl (0.005 to 0.01 mg/kg) and sodium pentobar-
bital (5 to 10 mg/kg) given intravenously. The anesthetics were
slowly titrated with supplemental doses given as needed during
the experiment. The dogs were intubated and mechanically
ventilated (Harvard Respirator, Harvard Apparatus, Millis,
Massachusetts, USA) with supplemental oxygen at four liters
per minute.
The right external jugular vein was exposed and a flow-
directed, balloon-tipped, thermodilution catheter (Model 93-
121A, 7 Fr., American Edwards Laboratories, Santa Ana,
California, USA) was advanced into the pulmonary artery.
Both femoral veins were cannulated with polyethylene cathe-
ters (PE 240) for intravenous infusions of inulin, radiocontrast
or saline for volume replacement. Both femoral arteries were
also cannulated. One arterial catheter was advanced into the
proximal aorta at least 6 cm above the renal arteries and was
used for infusion of either ANF or saline vehicle. The other
arterial catheter was placed in the infrarenal aorta and used for
blood sampling and on-line monitoring of arterial pressure.
A flank incision was made and the left kidney was exposed
via a retroperitoneal approach. The ureter was cannulated with
a short segment of polyethylene tubing(PE 150) for timed urine
collections. An electromagnetic flow probe was placed on the
left renal artery and connected to a flowmeter (Model FM 5010,
Carolina Medical Electronics, King, North Carolina, USA).
Renal blood flow, atrial pressures and arterial pressure were
recorded continuously on a strip recorder (Gould Model RS
3400, Gould Electronics, Minneapolis, Minnesota, USA).
After completion of the surgical preparations, a priming dose
of inulin was given and a constant infusion of I mi/mm was
begun in an effort to achieve a steady-state plasma inulin
concentration between 40 and 60 mg/dl. Following a 60-minute
equilibration period, a 30-minute baseline renal clearance was
performed. During this and subsequent clearance periods,
blood was drawn for hormonal analyses and determination of
inulin and sodium concentrations. Cardiac output, mean arterial
pressure, right and left atrial pressure, renal blood flow, and
urine flow were also measured during each clearance period.
Following baseline measurements, an infusion of either saline
vehicle (Group 4) or ANF, 30 ng/kg/min, (Group 5) was begun
into the suprarenal aorta at 1 mI/mm. A 20-minute lead-in period
was allowed, and a renal clearance was performed during the
second 10 minutes of this lead-in period. The radiocontrast
agent was then infused intravenously at a dose of 7 mI/kg over
a 10-minute period using a roller pump as in the chronic studies.
A renal clearance was performed during the last five minutes of
this radiocontrast infusion. The AN F/vehicle infusion was
continued for 30 minutes following the radiocontrast infusion
such that the total duration of this aortic infusion was one hour
as in the chronic studies. Three additional 30-minute recovery
clearances were then performed. Urinary volume losses were
replaced with intravenous saline given at the conclusion of each
clearance period.
Analyses
Glomerular filtration rate was determined by creatinine clear-
ance in the chronic studies and by inulin clearance in the acute
studies. Plasma and urinary creatinine concentrations were
measured by the Jaffe reaction (Beckman Instruments, Brea,
Louisiana, USA). Plasma and urinary inulin concentrations
were determined using the anthrone method [15]. Plasma and
urinary sodium concentrations were measured using ion-selec-
tive electrodes (Beckman Instruments). Urine osmolality was
determined using a vapor pressure osmometer (Model 5100 C,
Wescor, Inc., Logan, Utah, USA).
Cardiac output was measured by thermodilution (Cardiac
Output Model 9510-A computer, American Edwards Laborato-
ries, Irvine, California, USA). Systemic vascular resistance
was calculated by dividing the difference between mean arterial
and right atrial pressures by cardiac output. Pulmonary capil-
lary wedge pressure was used to determine left atrial pressure.
Blood for hormone analyses was placed in EDTA tubes,
immediately placed on ice and centrifuged at 2500 rpm at 4°C.
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Table 1. Changes in renal function in chronic experiments
Baseline
Days following radiocontrast injection
I day 2 days 3 days 4 days 5 days 6 days
Group 1: Normal (N = 5)
Ccrml/min 45.8 4.0 55.2 7.4 52.1 4.9 56.0 1.4 49.4 7.2 55.0 7.0 58.8 9.6
UV mi/mm 0.19 0.04 0.61 0.lO 0.18 0.04 0.23 0.04 0.24 0.05 0.23 0.05 0.23 0.04
UNaV pEq/min 28.1 4.7 69.0 ll.5a 27.3 7.6 29.0 4.9 31.0 5.7 39.0 6.8 30.4 9•4
FENa % 0.40 0.05 0.87 0.l5 0.45 0.09 0.34 0.06 0.42 0.06 0.47 0.05 0.33 0.08
Group 2: CHF (N = 5)
Ccr ml/mi,z 56.5 4.1 50.9 3.4 31.4 36a.b 34•5 37a,b.c 41.5 3.Oa 36.8 46.8 7.3
UV mI/mm 0,20 0.03 0.77 0.loa 0.19 0.04 0.21 0.06 0.48 0.29 0.23 0.05 0.16 0.02
UNaV pEqimin
FENa %
16.2 4.5
0.19 005b
60.8 6.6a
0.84 0.14a
16.2 8.8
0.33 0.17
13.2 6.3
0.26 0.12
23.7 11.6
0.37 0.19
14.2 71b
0.23 0.10"
12.5 7.3
0.16 0.09
Group 3: CHF/ANF (N = 5)
Ccrmi/min 43.8 4.8 46.5 11.4 40.0 8.1 55.0 5.9 42.3 3.2 43.0 3.3 47.0 7.7
UV mI/mm 0.24 0.07 0.67 0.05a 0.18 0.06 0.24 0.07 0.23 0.01 0.21 0.04 0.24 0.03
UNaV pEqimin
FENa%
5.4 3.5"
0.10 0.05'
46.6 11.1°
1.37 0.88a
8.4 4.7
0.11 0.06
11.2 6.6
0.12 0.06
6.4 4.2
0.11 0.07
5.2 2.8"
0,08 ÷ 004b
15.4 8.2
0.27 0.17
All data expressed as mean SEM.
a P < 0.05 vs. baseline
bP < 0.05 vs. normal group
C P < 0.05 vs. CHF/ANF group
Abbreviations are: Cr, creatinine clearance; UV, urine flow; UNaV, absolute sodium excretion; FENa, fractional excretion of sodium.
Plasma was separated and stored at —20°C until assay. Ex-
tracted arterial and venous plasma levels of ANF were mea-
sured by radioimmunoassay to a-ANF as previously described
[16]. Plasma renin activity was determined by radioimmunoas-
say using the method of Haber et al [17]. Aldosterone levels
were determined after dichloromethane extraction by radioim-
munoassay [18].
Data from each clearance period were averaged and are
expressed as mean standard error. For each of the experi-
mental protocols, comparisons with baseline within each group
were made by analysis of variance for repeated measures
followed by Dunnett's t-test. Comparisons between experimen-
tal groups were made using one-way analysis of variance
followed by unpaired Student's 1-test when appropriate. Statis-
tical significance was defined as P < 0.05.
Results
Chronic studies
At the time of radiocontrast injection, all paced dogs (Groups
2 and 3) had evidence of jugular venous distension by physical
examination and eight of ten had evidence of ascites as well.
The renal responses observed in the three experimental groups
during the protocol are presented in Table I. At baseline, there
was evidence of sodium retention in both CHF groups, but
there were no significant differences in baseline creatinine
clearance or urine flow between groups. In Group 1, the
controls, the intravenous infusion of radiocontrast was not
associated with any significant changes in daily creatinine
clearance over the next six days. Significant increases in urine
flow and sodium excretion were observed in the first day
following radiocontrast.
In Group 2, with experimental CHF, daily creatinine clear-
ance tended to decrease during the first day following radiocon-
trast administration and was significantly depressed below
baseline levels on the second through fifth days following
radiocontrast. The greatest average decrease in daily creatinine
clearance occurred on the second day after radiocontrast.
Although all Group 2 dogs experienced a decrease in daily
creatinine clearance, the maximum decreases ranged from 30 to
72 percent and averaged 44 percent. The depressed renal
function in Group 2 was not associated with significant de-
creases in urine flow or changes in sodium excretion.
In the dogs with CHF which received ANF with radiocon-
trast (Group 3), there were no significant decreases in daily
creatinine clearance following radiocontrast. In this group, as in
the others, significant increases in urine flow and sodium
excretion were observed during the first 24 hours following
radiocontrast. As shown in Figure 1, the changes in daily
creatinine clearance were significantly different in the group
with CHF alone compared with the normal and CHF/ANF
groups. The latter two groups did not differ significantly from
one another at any time.
20
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Fig. 1. Changes in daily creatine clearance (C,) compared with
baseline levels in chronic experiments. *D < 0.05 compared with
baseline; tP < 0.05 between groups. Abbreviations are: CHF, conges-
tive heart failure; ANF, atrial natriuretic factor. Symbols are: (•)
normal group; (A) CHF group; (•) CHF/ANF group.
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Table 2. Changes in hemodynamic and endocrine function in acute experiments
Baseline ANF/vehicle During contrast
Mmutes post-radiocontrast infusion
0—30 30—60 60—90 90—120
Group 4: Vehicle group (N = 6)
MAP mm Hg 94.8 6.0 97.2 4.2 84.7 6.9 102.5 3.9 97.3 6.8 93.7 8.6 96.5 7.7
RAP mm Hg 4.6 1.6 3.9 1.6 8.2 2.60 5.8 1.7 3.7 1.5 2.8 1.5 2.8 1.5
PCWPmm Hg 12.2 1.9 12.0 1.3 18.3 2.00 16.0 1.2 12.6 1.1 11.9 1.4 11.9 2.1
COliter/min 1.5 0.1 1.6 0.1 2.6 0.4* 1.6 0.2 1.3 0.1 1.1 0.1 1.1 0.1
SVR RU 61 4 60 6 32 40 61 5 75 7 82 80 89 70
ANF pg/mi 469 92 352 59 402 62 471 59 436 46 339 430 403 29
PRA ng/ml/hr 4.9 1.0 6.7 1.1 8.3 1.7 11.3 1.60 9.4 1.40 7.2 1.2 8.3 1.2
Aldo ngldi 64 32 72 36 50 30 60 28 76 26 90 24 101 28
Group 5: ANF group (N = 6)
MAP mm Hg 96.9 8.0 98.0 3.8 94.5 5.4 107.3 4.9 106.8 6.4 101.5 8.9 103.3 9.2
RAP mm Hg 8.2 2.3 6.7 1.8 12.8 2.00 8.3 1.9 6.3 1.7 5.3 1.6k 4.7 1.6k
PCWP mm Hg 17.6 1.6 16.5 1.9 22.2 1.80 20.6 2.0 16.8 13b 15.0 1.0 13.0 1.oa
CO liter/mm 1.8 0.2 1.9 0.2 2.5 0.30 2.0 0.2 1.3 0.1 1.2 o.r 1.1 0.10
SVRRU 55 14 52 8 36 80 56 10 80 120 83 130 90 120
ANF pg/mi 351 62 476 82 471 54 510 610 381 38 330 53 314 55
PRA ng/m!/hr 3.1 1.3 34 0.9k 7.3 1.9k 7.7 1.3 7,7 l.8 6.1 1.6 7.0 2.0
Aldo ng/dl 46 30 49 30 35 19
ANF-
45 24 60 26 67 26 78 280
All data expressed as mean SEM.
a p < 0.05 vs. baseline
b P < 0.05 vs. vehicle group
Abbreviations are: MAP, mean arterial pressure; RAP, right atrial pressure; PCWP, pulmonary capillary wedge pressure; CO. cardiac output;
SVR, systemic vascular resistance; RU, resistance units (mm Hg/liter/mm); ANF, atrial natriuretic factor; PRA, plasma renin activity; Aldo,
plasma aldosterone.
Reference values for normal anesthetized dogs: MAP 122 7, RAP 2.0 0.9, PCWP 3.3 0.6, CO 2.9 0.5, SVR 47 7, ANF 58 17, PRA
3.9 0.8, Aldo II 2.
Table 3. Changes in renal function in acute experiments
Baseline ANF/vehicle During contrast
Mm utes post-radiocontrast infusion
0—30 30—60 60—90 90—120
Group 4: Vehicle group (N = 6)
GFR mI/mm 26.9 4,7 26.7 5.0 17.2 3.80 18.9 3.00 21.8 3.5 22.6 2.7 23.8 3.5
RBF mi/mm 87 20 93 20 113 27 99 20 78 14 73 14 69 13
UV mi/mm 0.13 0.04 0.15 0.04 2.79 l.19a 2.83 0.66a 1.92 0.440 1.17 0.26 0.90 0.20
UN0 pEq/min 5 1 9 5 202 990 195 590 124 40 65 21 46 16
FEN0 % 0.14 0.05 0.27 0.11 7.31 2.70a 6.79 1.220 3.54 0.680 2.08 0.39 1.37 0.26
U0,m mOsm/kg 940 285 1011 258 566 172 389 360 433 500 479 62 440 680
Group 5: ANF group (N = 6)
GFR mi/mm 22.1 3.6 32.1 4,70 27.4 3.5 24.8 3.6 23.6 5.5 21.7 4.6 23.3 4.9
RBF mi/mm 126 30 135 27 187 430 183 460 119 30 83 21 83 21
UV mi/mm 0.21 0.05 0.40 0.13 3.56 1.110 4.20 1.120 2.72 0.750 1.63 0.410 1.18 0.30
UNaV pEq/mmn
FENO %
10 2b
0.29 0.04"
31 10
0.62 0.13
302 1190
5.98 2.48a
380 1400
9.43 2.28
273 1130
6.43 1.480
171 73
4.47 l.24a
116 53
2.93 0.96
Uøm mOsm/kg 969 77 788 780
-
415 37
ANF
376 19* 394 25 448 310 497 50a
All data are expressed as mean SEM.
0 P < 0.05 vs. baseline
b P < 0.05 vs. vehicle group
Abbreviations are: GFR, glomerular filtration rate; RBF, renal blood flow; UV, urine flow; UNOV, absolute sodium excretion; FENa, fractional
excretion of sodium; Uøsm, urine osmolality.
served during the acute experimental protocol are presented in
Table 2 and the single kidney renal hemodynamic and excretory
responses are presented in Table 3. Normal hemodynamic and
hormonal reference values from recent studies in pentobarbital
anesthetized dogs from our laboratory [14] are presented in
Table 2 for comparison. In the two groups of dogs with CHF
Acute studies from the present study, baseline arterial pressure and cardiac
The systemic hemodynamic and hormonal responses ob- output were reduced in association with significant increases in
atrial pressures, circulating ANF and aldosterone. There were
no significant differences between the two CHF groups at
baseline with the exception of slightly increased sodium excre-
tion in Group 5.
In Group 4, there were no significant changes associated with
intraaortic administration of saline vehicle. In this group, radi-
I
ANFNehicIe
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ocontrast infusion produced transient, but significant, changes
in systemic hemodynamics including increases in atrial pres-
sures and cardiac output and decreases in systemic vascular
resistance. Significant decreases in GFR occurred during and
after radiocontrast despite maintenance of renal blood flow and
marked increases in urine flow and sodium excretion. In addi-
tion, significant decreases in urine osmolality were observed
during the first 60 minutes following radiocontrast.
In Group 5, the intraaortic ANF infusion was not associated
with significant systemic hemodynamic changes, but did pro-
duce a 45 percent increase in GFR and a small decrease in urine
osmolality. During continued ANF infusion, the radiocontrast
infusion failed to reduce GFR below baseline levels as was
observed in the Group 4 controls (Fig. 2). After discontinuation
of the ANF infusion, GFR did not decrease below baseline
levels. The radiocontrast infusion in the presence of infused
ANF was also associated with significant increases in renal
blood flow. Despite these differential renal hemodynamic re-
sponses to radiocontrast, the transient changes in urine flow
and sodium excretion following radiocontrast did not differ
between the two experimental groups. In the dogs receiving
ANF, significant decreases in urine osmolality also were ob-
served during and after radiocontrast.
Discussion
The present studies were designed to investigate the renal
effects of intravenous radiocontrast in congestive heart failure
and the ability of ANF to modulate these responses. The major
findings of these studies are that in normal controls, intravenous
infusion of radiocontrast does not produce significant reduc-
tions in daily creatinine clearance in contrast to consistent
reductions in daily creatinine clearance during the five days
following radiocontrast administration in dogs with experimen-
tal CHF. Further, pharmacologic concentrations of ANF im-
portantly prevent this radiocontrast-induced renal dysfunction
in the conscious dog with experimental CHF. The acute studies
demonstrate that in this model of RCIN, the reduction in GFR
appears biphasic, and that the action of ANF may be to increase
GFR prior to radiocontrast thus allowing a maintenance of GFR
during and immediately after radiocontrast exposure.
The volume of radiocontrast used in this study, 7 ml/kg, was
the same as in previously described animal models of RCIN [3,
4] and represents a large, but not unreasonable, dose of 490 ml
for a 70 kg human. In chronic clearance studies we observed
that euvolemic normal dogs did not experience significant
decreases in daily creatinine clearance following this large
intravenous infusion of iodinated radiocontrast. This is consis-
tent with previous studies in both experimental animals [3, 4]
and humans [19—21] which have found a low incidence of RCIN
in the absence of one or more known risk factors.
Until recently, the lack of an adequate animal model has
limited advancements in the understanding and treatment of
RCIN. However, two recent reports by Vari et al [3] and
Heyman et al [4] have provided important pathophysiologic
insights into RCIN through the induction of acute renal failure
in normal animals following an intravenous infusion of radio-
contrast. In each of these studies, both chronic sodium restric-
tion, with consequent activation of the renin-angiotensin sys-
tem, and inhibition of prostaglandin synthesis with indomethacin
were required to produce decreases in daily creatinine clear-
ance following radiocontrast. While supporting the notion of
multiple renal insults contributing to the development of RCIN,
these studies also correlate with clinical observations which
indicate an increased risk of RCIN in dehydrated patients and
patients with a tendency towards renal vasoconstriction and/or
disorders or autoregulation [22]. The latter category includes
congestive heart failure, advanced liver disease, diabetic
nephropathy and chronic renal failure.
The present studies represent an extension of these important
animal models of RCIN and confirm the link between these
models and CHF, a pathophysiologic state which predisposes
to RCIN [12]. The model of CHF used in this study is
associated with a pattern of cardiovascular, renal and neuro-
humoral abnormalities characteristic of primary myocardial
failure. As demonstrated by previous studies in our laboratory,
these abnormalities include: decreased cardiac output and
arterial pressure, increased atrial pressures, avid sodium reten-
tion and activation of ANF, the renin-angiotensin-aldosterone
system and the adrenergic nervous system [13, 14]. Moreover,
studies by Reigger, Elsner and Kromer [23] demonstrate that
pacing-induced CHF, like CHF in humans [24], is critically
dependent on prostaglandins for maintenance of renal hemody-
namic function. In dogs with experimental CHF, we observed
that intravenous radiocontrast consistently produces moderate
*1. t
U-
1
20
10
0•
—10
—20
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Before During
radiocontrast radiocontrast
Fig. 2. Changes in glomerular filtration rate
(GFR) compared with baseline levels in acute
experiments. < 0.05 compared with
baseline; tP < 0.05 between groups.
Abbreviation is ANF, atrial natriuretic factor.
0—30 30—60 60—90 90—120 Symbols are: () CHF group; (•) CHF/ANF
Minutes following radiocontrast group.
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decreases in daily creatinine clearance over the next five days,
with the greatest impairment occurring during the second day
after radiocontrast. The time course of this renal dysfunction is
similar to that described in humans [25, 26]. Thus, pacing-
induced CHF in dogs provides the basis for a clinically relevant
animal model of RCIN which importantly extends the results of
previously described models into a pathophysiologic condition.
To better characterize the development of RCIN in CHF, the
current studies examined the systemic and renal hemodynamic
changes occurring acutely during and after radiocontrast infusion.
The transient, but striking, 50 percent decrease in systemic
vascular resistance observed during radiocontrast infusion is con-
sistent with previous studies indicating that radiocontrast is a
potent vasodilator in extrarenal vascular beds [27]. However,
unlike most previous studies [27—34], we did not observe a renal
vasoconstrictor response during or after radiocontrast. This dif-
ference may relate to the 10-minute intravenous infusion of
radiocontrast used in this study which differs from the small
intrarenal boluses of radiocontrast used in most previous studies
[27—34]. In fact, one study [35] which utilized a somewhat larger (2
mllkg) radiocontrast injection reported a longer renal vasodilator
phase than most studies using small intrarenal boluses. CHF itself
may also provide an alternative explanation for the absence of
radiocontrast-induced vasoconstriction in that recent studies indi-
cate a blunted renal blood flow response to intrarenal hypertonic
saline in heart failure [36].
In the present studies, we observed a significant (35.6%)
decrease in GFR during the last five minutes of radiocontrast
infusion. The decrease in GFR persisted during the first 30
minutes following radiocontrast then returned towards baseline
levels. Of the few studies that have described changes in GFR
following radiocontrast, some have described significant de-
creases [30—31], while others have failed to observe any signif-
icant acute changes [33—34]. In studies describing decreases in
GFR following radiocontrast [30—31], the magnitudes of the
decreases (42 and 31%) were similar to that observed in the
present study. Once again, these studies employed small doses
of radiocontrast injected directly into the aorta or renal artery of
normal dogs.
The decrease in GFR following radiocontrast in association
with stable or increased renal blood flow suggest a decrease in
whole kidney filtration fraction. This apparent decrease in
filtration fraction is consistent with the findings of Van et al [3]
in which changes in the glomerular ultrafiltration coefficient
were observed during renal dysfunction following radiocon-
trast. Thus, an analogous decrease in the ultrafiltration coeffi-
cient might have occurred in the present studies. However, we
cannot exclude the possibility of changes in afferent and ef-
ferent arteriolar resistances or altered intrarenal blood flow
distribution, which could also produce apparent decreases in
whole kidney filtration fraction.
The temporal pattern of the decrease in GFR in response to
hypertonic ionic radiocontrast observed in the present study is
similar to that produced by intrarenal infusion of hypertonic
saline in previous studies assessing whole kidney tubuloglomer-
ular feedback (TGF) responses [36—40]. Two of the studies have
demonstrated intact GFR responses to intrarenal hypertonic
saline in the presence of experimental CHF [36, 39] which is
consistent with the GFR responses in the present studies. Of
further relevance to the current investigations, ANF has been
demonstrated to significantly attenuate TGF-mediated de-
creases in GFR [36, 40, 41]. Studies by Loftus, Redfield and
Burnett [41] suggested that the action of ANF could be to
antagonize the effects of adenosine, a proposed mediator of
TGF. A possible link between adenosine and renal hemody-
namic responses to radiocontrast is strengthened by the studies
of Arend et al [31], who reported that decreases in GFR
following radiocontrast were attenuated by pretreatment with
theophylline, an adenosine receptor antagonist, and augmented
by dipyndamole, a potentiator of adenosine. Moreover, both
adenosine-induced mesangial contraction and acute GFR re-
sponses to radiocontrast are attenuated by pretreatment with
calcium entry blockers [30, 42]. From this perspective, it is
possible that hypertonic radiocontrast medium triggers in-
creases in solute transport and reabsorptive work with conse-
quent adenosine generation. Importantly, the return of GFR
towards baseline levels during the two hours following radio-
contrast suggests that decreases in daily creatinine clearance
observed in the chronic experiments (Group 2) are not simply a
continuation of early reductions in renal function, but rather a
late sequela which may be potentiated by early renal hemody-
namic responses to radiocontrast.
Based on its physiologic properties, we speculated that ANF
may attenuate RCIN in dogs with CHF. In addition to its
preferential renal hemodynamic actions and unique ability to
increase GFR at pharmacologic doses [5], ANF has demon-
strated prophylactic and therapeutic effects in several animal
models of acute ischemic renal failure produced by renal artery
clamping [7—9], norepinephrine [10] and hypotensive hemor-
rhage [11]. In these previous studies, pharmacologic doses of
ANF produced increases in GFR when administered before
and/or after a known stimulus for acute renal failure. Moreover,
recent studies in normal dogs [34] and preliminary studies in
humans [43] indicate that exogenous ANF blocks acute reduc-
tions in renal blood flow following radiocontrast.
In the present studies, the 30 ng/kglmin dose of ANF infused
into the suprarenal aorta was designed to produce pharmaco-
logic renal plasma levels of ANF while avoiding systemic
hypotension, as suggested by Nakamoto et al [7]. When admin-
istered in this manner, ANF prevented both acute and chronic
decreases in renal function following intravenous radiocontrast
in dogs with CHF. In the acute experiments, the ANF infusion
significantly increased GFR prior to radiocontrast administra-
tion. This increase in GFR was not associated with any signif-
icant systemic hemodynamic effects. In contrast, when Redfield
et al [44] gave higher doses of ANF intravenously to dogs with
low cardiac output, there was no increase in GFR and a
tendency towards hypotension, underscoring the importance of
intraaortic administration in the present study.
When radiocontrast was given in the presence of intraaortic
infusion of ANF, the renal hemodynamic responses to radio-
contrast were significantly altered. In addition to increases in
whole kidney renal blood flow which persisted for 30 minutes
following radiocontrast, GFR did not decrease below baseline
levels. This maintenance of GFR was primarily due to the
increase in GFR prior to radiocontrast rather than significant
attenuation of the GFR response to radiocontrast itself. When
ANF was discontinued, GFR did not decrease below baseline
levels indicating either a sustained effect of ANF or an attenu-
ation of the stimulus for decreased GFR. Most importantly, as
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shown by the chronic experiments, the same aortic infusion of
ANF which maintained GFR acutely prevented subsequent
reductions in creatinine clearance. This observation suggests
that although acute changes in renal function following radio-
contrast are not sustained, they probably do contribute to later
sequelae including RCIN.
This biphasic renal response is consistent with the concept of
an initiating hemodynamic mechanism which contributes to a
separate maintenance phase as advanced for ischemic renal
failure [45]. In acute post-ischemic renal failure, as opposed to
nephrotoxic acute renal failure, studies by Patak, Lifschitz and
Stein [46] suggest that early renal hemodynamic responses to an
ischemic insult are critical determinants of later renal functional
impairment which may occur through multiple mechanisms
including persistent renal vasoconstriction, decreased glomer-
ular permeability, tubular obstruction or backleakage of filtrate.
Moreover, interference with these initial hemodynamic re-
sponses may be protective against later renal dysfunction [461.
From this perspective, the ability of ANF to increase renal
blood flow and maintain GFR during and following radiocon-
trast may, in part explain its protective action against RCIN. To
the degree that ischemia contributes to RCIN, early ANF-
mediated increases in renal blood flow, and perhaps medullary
perfusion, may help ameliorate cellular hypoxia. This perspec-
tive is consistent with the studies of Heyman et al [4] which
implicated medullary hypoxia in their model of RCIN.
Other possible mechanisms for the preventive effects of ANF
relate, in general, to current theories about the pathophysiology
of RCIN. For example, maintenance of GFR during and after
radiocontrast infusion may enhance clearance of radiocontrast
and might decrease direct tubular toxicity attributable to radio-
contrast. Studies reporting extensive proximal tubule vacu-
olization [4, 47] or enzymuria [48, 49] following radiocontrast
are consistent with direct tubular toxicity, but these findings
have not consistently correlated with changes in renal function.
Alternatively, ANF may prevent tubular stasis and/or cytotox-
icity by promoting high urine flow rates. Finally, pharmacologic
levels of ANF antagonize angiotensin Il-mediated mesangial
cell contraction [6], a mechanism of reduced renal function
implicated in the studies of Van et al [3].
In summary, the present studies importantly identify exper-
imental CHF in the dog as a clinically relevant animal model of
RCIN. These studies therefore extend the findings of two
recently described models of RCIN [3, 4] and confirm their link
with CHF, a pathophysiologic state which predisposes to RCIN
in humans. These studies demonstrate, for the first time, that
pharmacologic renal levels of ANF prevent the development of
RCIN. Further, the current investigations suggest that this
action of ANF may be related to its ability to increase GFR and
thus prevent acute reductions in GFR in response to radiocon-
trast.
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